Application 211412
- Type
- ANDA
- Sponsor
- YILING PHARM LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | CELECOXIB | CELECOXIB | CAPSULE;ORAL | 50MG | No | No |
| 002 | CELECOXIB | CELECOXIB | CAPSULE;ORAL | 100MG | No | No |
| 003 | CELECOXIB | CELECOXIB | CAPSULE;ORAL | 200MG | No | No |
| 004 | CELECOXIB | CELECOXIB | CAPSULE;ORAL | 400MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211412-001 | CELECOXIB | CELECOXIB | 50MG | CAPSULE / ORAL | AB | 2020-03-06 | |
| A211412-002 | CELECOXIB | CELECOXIB | 100MG | CAPSULE / ORAL | AB | 2020-03-06 | |
| A211412-003 | CELECOXIB | CELECOXIB | 200MG | CAPSULE / ORAL | AB | 2020-03-06 | |
| A211412-004 | CELECOXIB | CELECOXIB | 400MG | CAPSULE / ORAL | AB | 2020-03-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211412-001 | AB |
| A211412-002 | AB |
| A211412-003 | AB |
| A211412-004 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A211412-001 | CELECOXIB | 50MG | CAPSULE / ORAL | AB | 2020-03-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A211412-002 | CELECOXIB | 100MG | CAPSULE / ORAL | AB | 2020-03-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A211412-003 | CELECOXIB | 200MG | CAPSULE / ORAL | AB | 2020-03-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A211412-004 | CELECOXIB | 400MG | CAPSULE / ORAL | AB | 2020-03-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A211412-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A211412-002 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A211412-003 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A211412-004 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Celecoxib | CELECOXIB | Avet Pharmaceuticals Inc. | 4bc96d0c-b484-3cee-e063-6294a90a9193 | 2026-03-15 | Boxed warning, Warnings, Adverse reactions | 211412 ANDA211412 |
| Celecoxib | CELECOXIB | Yiling Pharmaceutical, Inc. | 43979279-867b-4303-8f30-fc58ae75a069 | 2025-12-29 | Boxed warning, Warnings, Adverse reactions | 211412 ANDA211412 69117-0022 69117-0023 69117-0021 69117-0020 |
| Celecoxib | CELECOXIB | Chartwell RX, LLC | a99a67f3-ccaa-4d54-8922-d6dd30fba274 | 2025-12-10 | Boxed warning, Warnings, Adverse reactions | 211412 ANDA211412 62135-021 62135-023 62135-022 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 62135-021 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-021 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-021 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-022 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-022 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-022 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-023 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-023 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 62135-023 | Celecoxib | Celecoxib | Chartwell RX, LLC | ANDA | Current |
| 69117-0020 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0020 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0020 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0020 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0021 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0021 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0021 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0021 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0022 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0022 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0022 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0022 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0023 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0023 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0023 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 69117-0023 | Celecoxib | Celecoxib | Yiling Pharmaceutical, Inc. | ANDA | Current |
| 81288-020 | Celecoxib | Celecoxib | EMC PHARMA, LLC | ANDA | Current |
| 81288-021 | Celecoxib | Celecoxib | EMC PHARMA, LLC | ANDA | Current |
| 81288-022 | Celecoxib | Celecoxib | EMC PHARMA, LLC | ANDA | Current |
| 81288-023 | Celecoxib | Celecoxib | EMC PHARMA, LLC | ANDA | Current |